 ENGLEWOOD, Colo., April 19, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that Ampios lead drug candidate, AmpionTM, provides some of the same anti-inflammatory effects as the steroid dexamethasone but without the significant adverse events associated with steroids. 